Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Depreciation and Depletion (2017 - 2025)

Aclaris Therapeutics has reported Depreciation and Depletion over the past 9 years, most recently at $100000.0 for Q3 2025.

  • Quarterly results put Depreciation and Depletion at $100000.0 for Q3 2025, down 50.0% from a year ago — trailing twelve months through Sep 2025 was $400000.0 (down 50.0% YoY), and the annual figure for FY2024 was $700000.0, down 12.5%.
  • Depreciation and Depletion for Q3 2025 was $100000.0 at Aclaris Therapeutics, roughly flat from $100000.0 in the prior quarter.
  • Over the last five years, Depreciation and Depletion for ACRS hit a ceiling of $200000.0 in Q1 2021 and a floor of $100000.0 in Q4 2022.
  • Median Depreciation and Depletion over the past 5 years was $200000.0 (2021), compared with a mean of $173684.2.
  • Biggest five-year swings in Depreciation and Depletion: crashed 50.0% in 2022 and later skyrocketed 100.0% in 2023.
  • Aclaris Therapeutics' Depreciation and Depletion stood at $200000.0 in 2021, then crashed by 50.0% to $100000.0 in 2022, then skyrocketed by 100.0% to $200000.0 in 2023, then crashed by 50.0% to $100000.0 in 2024, then changed by 0.0% to $100000.0 in 2025.
  • The last three reported values for Depreciation and Depletion were $100000.0 (Q3 2025), $100000.0 (Q2 2025), and $100000.0 (Q1 2025) per Business Quant data.